The primary objective of this Phase I/II study is the establishment of the safety of cidofovir infiltration of HPV lesions following laser ablation. We will evaluate the use of six months of suppressive oral acyclovir therapy in neonates following herpes simplex virus disease involving the central nervous system. This is a double-blind, randomized study. Following 21 days of IV acyclovir, neonates will be randomized to receive suppressive acyclovir therapy or to receive identically flavored placebo for a period of six months. Cutaneous HSV recurrences in either group will be treated with open label oral acyclovir. This study will make possible assessment of the potential benefits/risks of suppressive acyclovir therapy in decreasing morbidity and neurologic impairment.
Showing the most recent 10 out of 570 publications